DAILY UPDATE: Human Genome Project as the Dow and NASDAQ Diverge

MEDICAL EXECUTIVE-POST TODAY’S NEWSLETTER BRIEFING

***

Essays, Opinions and Curated News in Health Economics, Investing, Business, Management and Financial Planning for Physician Entrepreneurs and their Savvy Advisors and Consultants

Serving Almost One Million Doctors, Financial Advisors and Medical Management Consultants Daily

A Partner of the Institute of Medical Business Advisors , Inc.

http://www.MedicalBusinessAdvisors.com

SPONSORED BY: Marcinko & Associates, Inc.

***

http://www.MarcinkoAssociates.com

Daily Update Provided By Staff Reporters Since 2007.
How May We Serve You?
© Copyright Institute of Medical Business Advisors, Inc. All rights reserved. 2025

REFER A COLLEAGUE: MarcinkoAdvisors@outlook.com

SPONSORSHIPS AVAILABLE: https://medicalexecutivepost.com/sponsors/

ADVERTISE ON THE ME-P: https://tinyurl.com/ytb5955z

Your Referral Count -0-

***

CITE: https://www.r2library.com/Resource

When it comes to scientific achievements that have advanced the practice of medicine, you’d be hard-pressed to find one more influential than the Human Genome Project. The project, a federally funded collaboration between scientists around the globe, began in October 1990 with the goal of improving our knowledge of human biology by sequencing an entire human genome, which is the complete set of DNA in a cell. Nearly 13 years and $2.7 billion later, the project wrapped up in April 2003, and scientists around the world now use the reference human genome to study genetics, biology, and more. Today, the entire human genome can be sequenced in as little as five hours and costs as little as $600. Learn more about the Human Genome Project’s impact here.

CITE: https://tinyurl.com/2h47urt5

🟢 What’s up

  • Jack in the Box popped like a…well, you know…after activist investor Biglari Capital reportedly accrued a 10% stake in the fast-food company. Shares rose 7.86%.
  • Robinhood Markets climbed 6.12% on speculation that it may be added to the S&P 500 to fill the spot left by Juniper Networks.
  • Rigetti Computing rose 15.45% after Cantor Fitzgerald analysts initiated their coverage of the quantum computing company with an “overweight” rating.
  • Verint Systems jumped 15.33% on reports that the customer service software maker may be acquired by Thoma Bravo.
  • Corona parent company Constellation Brands gained 4.48% after it reiterated its fiscal guidance, assuring shareholders that aluminum tariffs will only cost the company about $20 million.
  • Crypto companies gained across the board after bitcoin miner BitMine Immersion Technologies announced it’s pivoting to ethereum. BitMine rose 21.17%, MARA Holdings gained 13.38%, and CleanSpark climbed 12.64%.

What’s down

  • Centene plunged 40.37% after the health insurer rescinded its fiscal 2025 guidance, warning that EPS will come in lower than anticipated.
  • Centene’s news pulled the rest of the health insurance industry down with it. UnitedHealth Group lost 5.70%, CVS Health fell 4.28%, Elevance Health stumbled 11.50%, and Molina Healthcare dropped 21.97%.
  • Paramount Global sank 2.43% after the company settled its 60 Minutes lawsuit with President Trump for $16 million.
  • Marvell Technology slipped 2.61% on reports that Microsoft is cutting back on manufacturing AI chips in-house.
  • Intel lost 4.25% on the news that it may be shifting the strategy behind its foundry business.

CITE: https://tinyurl.com/tj8smmes

Visualize: How private equity tangled banks in a web of debt, from the Financial Times.

COMMENTS APPRECIATED

PLEASE SUBSCRIBE: MarcinkoAdvisors@outlook.com

Thank You

***

***

***

***

EDUCATIONAL TEXTBOOKS: https://tinyurl.com/4zdxuuwf

***

DAILY UPDATE: Stablecoins & 23andMe

MEDICAL EXECUTIVE-POST TODAY’S NEWSLETTER BRIEFING

***

Essays, Opinions and Curated News in Health Economics, Investing, Business, Management and Financial Planning for Physician Entrepreneurs and their Savvy Advisors and Consultants

Serving Almost One Million Doctors, Financial Advisors and Medical Management Consultants Daily

A Partner of the Institute of Medical Business Advisors , Inc.

http://www.MedicalBusinessAdvisors.com

SPONSORED BY: Marcinko & Associates, Inc.

***

http://www.MarcinkoAssociates.com

Daily Update Provided By Staff Reporters Since 2007.
How May We Serve You?
© Copyright Institute of Medical Business Advisors, Inc. All rights reserved. 2025

REFER A COLLEAGUE: MarcinkoAdvisors@outlook.com

SPONSORSHIPS AVAILABLE: https://medicalexecutivepost.com/sponsors/

ADVERTISE ON THE ME-P: https://tinyurl.com/ytb5955z

Your Referral Count -0-

CITE: https://www.r2library.com/Resource

The world’s two biggest retailers, Amazon and Walmart, are looking into issuing their own stablecoins for US customers to use at checkout instead of credit or debit cards, the Wall Street Journal reportedy. Other big companies, including Expedia and some airlines, are also considering the move.

CITE: https://tinyurl.com/2h47urt5

CITE: https://tinyurl.com/tj8smmes

23andMe founder Anne Wojcicki is poised to regain control of the company because a nonprofit she controls outbid Regeneron Pharmaceuticals for its assets in a bankruptcy auction, offering $305 million. Wojcicki’s return to power over the company—and its DNA data—comes as a surprise after 23andMe announced last month that Regeneron had won the bidding (it got reopened because the nonprofit made an unsolicited bid).

Visualize: How private equity tangled banks in a web of debt, from the Financial Times.

COMMENTS APPRECIATED

PLEASE SUBSCRIBE: MarcinkoAdvisors@outlook.com

Thank You

***

***

***

***

EDUCATIONAL TEXTBOOKS: https://tinyurl.com/4zdxuuwf

***

23andMe Files for Bankruptcy

By Staff Reporters

BREAKING NEWS

***

***

Deoxyribonucleic acid or DNA is a polymer composed of two polynucleotide chains that coil around each other to form a double helix. The polymer carries genetic instructions for the development, functioning, growth and reproduction of all known organisms and many viruses.

***

The 23andMe Public Company

The genetic testing company 23andMe went from biotech superstar to the brink of collapse. And, its most valuable asset might be its controversial customer DNA data trove.

More: http://www.23andme.com

Now, 23andMe filed for bankruptcy late Sunday night and announced the resignation of its chief executive officer Anne Wojcicki who is stepping down from her position but remains on the board of directors.

Wojcicki has so far tried unsuccessfully to rescue the business by buying it back and capping a precipitous fall for the DNA-testing company.

MORE: https://tinyurl.com/38rtfjck

COMMENTS APPRECIATED

Read, Like, Refer and Subscribe

***

***

GOING PRIVATE: 23andMe?

By Staff Reporters

***

***

On September 16th, 2024, ancestry and genetics-testing company 23andMe has agreed to pay a $30 million settlement after a class-action lawsuit was brought against the company for last year’s data breach.

The settlement, which is pending a judge’s approval, comes after the company confirmed in October that “threat actors” used about 14,000 accounts, approximately 0.1% of the company’s user base, to access the ancestry data of 6.9 million connected profiles. Leaked data included users’ account information, location, ancestry reports, DNA matches, family names, profile pictures, birth dates and more.

CEO’s plan to take it private?

And so, all seven of the struggling DNA testing company’s independent directors just stepped down from its board of directors, leaving only founder and CEO Anne Wojcicki. A committee formed by the board had previously rejected Wojcicki’s plan to take the company private, concluding that it didn’t offer a high enough premium to shareholders. Wojcicki persisted with her efforts, but in their resignation, the directors said they still hadn’t seen a “fully financed, fully diligenced, actionable proposal,” so they couldn’t agree on the strategic direction forward.

The CEO said in a memo to employees that she was “surprised and disappointed” by their decision.

COMMENTS APPRECIATED

Thank You

***

***

DAILY UPDATE: Genome Testing, the Stock Markets and Microsoft, Apple & Meta

MEDICAL EXECUTIVE-POST TODAY’S NEWSLETTER BRIEFING

***

Essays, Opinions and Curated News in Health Economics, Investing, Business, Management and Financial Planning for Physician Entrepreneurs and their Savvy Advisors and Consultants

Serving Almost One Million Doctors, Financial Advisors and Medical Management Consultants Daily

A Partner of the Institute of Medical Business Advisors , Inc.

http://www.MedicalBusinessAdvisors.com

SPONSORED BY: Marcinko & Associates, Inc.

***

http://www.MarcinkoAssociates.com

Daily Update Provided By Staff Reporters Since 2007.
How May We Serve You?
© Copyright Institute of Medical Business Advisors, Inc. All rights reserved. 2024

REFER A COLLEAGUE: MarcinkoAdvisors@msn.com

SPONSORSHIPS AVAILABLE: https://medicalexecutivepost.com/sponsors/

ADVERTISE ON THE ME-P: https://tinyurl.com/ytb5955z

***

Apple and Meta are considering an AI partnership. The two tech giants are discussing integrating Meta’s generative AI model into Apple’s new AI platform, Apple Intelligence, the WSJ reports. Instead of building an in-house AI model, Apple opted for the partnership route and previously announced a deal with OpenAI to bring ChatGPT to iPhones. Apple has also reportedly held talks with AI startups Anthropic and Perplexity to fuse their AI models with Apple Intelligence and get that sweet, sweet distribution Apple provides.

CITE: https://www.r2library.com/Resource

Genome testing can spot rare disease risks at birth. Newborn babies typically get blood tested for dozens of diseases, but some parents living in North Carolina and New York have recently been able to get their bundles of joy screened for hundreds of potentially life-threatening medical conditions that regular tests can’t catch thanks to a growing field called genomic medicine. Early results from two ongoing studies are very promising, the Washington Post reported, but scaling the new type of testing could be tricky: A full genome read (which covers all of your DNA) costs around $1,000 per patient. Still, research into the cost-benefit of genome sequencing has found that it can ultimately save families money on hospital care.

CITE: https://tinyurl.com/2h47urt5

Markets: Sweating the upcoming election? Investors aren’t. The S&P 500 is on track for its best first-half performance in an election year going back to 1976, per Dow Jones Market Data. And as trading begins Monday morning, Microsoft is back on the Iron Throne as the US’ most valuable company following Nvidia’s stumbles at the end of last week.

CITE: https://tinyurl.com/tj8smmes

COMMENTS APPRECIATED

PLEASE SUBSCRIBE: MarcinkoAdvisors@msn.com

Thank You

***

***

***

***

EDUCATIONAL TEXTBOOKS: https://tinyurl.com/4zdxuuwf

***

Craig Venter Unveils Synthetic Life

Some Positive News on Memorial Weekend 2024

By Dr. David Edward Marcinko; MBA, MEd, CMP™

Was Artificial Life Created A Decade Ago?

According to Craig Venter “synthetic life” was created. Venter is the American biologist and entrepreneur most famous for his role in being one of the first to sequence the human genome. He has now reportedly synthesized the first artificial cell.

I don’t know about you, but this is huge news – regardless of whether you call it “life” or not.

An Arm Chair Philosopher

Now, I am not speaking as a doctor or scientist; but rather as an armchair economist and philosopher recalling my undergraduate days at Loyola University Maryland, under the tutelage of the late Aldo Tassi PhD. So, I repeat, this was huge news and an interesting piece of science. It is historic, and has large implications for the future and even the economy. Why?

The Invisible Hand

Much of our time here at the ME-P is spent integrating the hard and soft sciences of practice management, economics and financial planning for a medical audience. But occasionally, negative situations, political cycles and pessimistic opinions on our topic channels are expressed. These disparaging political remarks even indirectly target the USA and our very survival as a free nation and self-governing people.

IOW: Contrary to innovations, and innovators, like Craig Venter.

Nevertheless, there an “invisible hand” – call it economics or capitalism – that keeps us moving in the direction of survival. And, we are conscious beings capable of controlling the rate of that progression in all fields of human endeavor.

What it Is

A chromosome was designed in digital code on a computer and then transplanted into a bacterial cell, transforming that cell into a new bacterial species. Apart from the usual blueprint for proteins, the DNA also carried the names of the key contributors and even its own email address.

How it Works

As reported according to Venter, “This is the first self-replicating species on the planet, whose parent is a computer.”

And, he has already mentioned some potential practical applications for his discovery: a vaccine for HIV and a new strain of algae that can significantly decrease CO2-levels and provide a source for gasoline.

Assessment

And so, on this Memorial Weekend – a day for remembering death and sacrifice – let us celebrate life and achievement instead by stating that we are not apologists for the USA.

As the last best hope for this planet, we are not always right or politically correct, but this country offers the greatest opportunity on earth for human advancement, capitalism and success through conscientious work effort.

We do not believe America has seen better days. Those who fought did not die in vain. Better days are still in our future. We are optimistic about the long-term future of our country when looking at our progression to ameliorate the planet’s ills, to-date. We have come out of hard times before – like the current recession – by taking innovative steps forwards, not backwards. While we are likely to go through a period of adjustment in the near-term, the end result will be further individual, national and private progress in the USA. God Bless America.

Rest assured, we will continue to lead and create the world, much like Crag Venter created artificial life. Candor – Intelligence – Goodwill to all

Conclusion

And so, your thoughts and comments on this ME-P are appreciated. What do you think of this development? What economic discoveries, medical cures, life enhancing inventions and/or break-thru innovations will this creation open up?

Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, be sure to subscribe. It is fast, free and secure.

Channel Surfing the ME-P

Have you visited our other topic channels? Established to facilitate idea exchange and link our community together, the value of these topics is dependent upon your input. Please take a minute to visit. And, to prevent that annoying spam, we ask that you register. It is fast, free and secure.

Conclusion

Your thoughts and comments on this ME-P are appreciated. Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, subscribe to the ME-P. It is fast, free and secure.

Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Medical Executive-Post – is available for seminar or speaking engagements. Contact: MarcinkoAdvisors@msn.com

OUR OTHER PRINT BOOKS AND RELATED INFORMATION SOURCES:

Product DetailsProduct Details

Cigna Sells Medicare Part C as 23andMe Crashes

By Staff Reporters

HCSC will acquire Cigna’s Medicare Advantage, Part D, supplemental benefits and CareAllies businesses, and the parties expect the deal to close in the first quarter of 2025. And, as January exits, we enter the thick of earnings call season. This week executives at AbbVie, Cigna, and Merck—to name a few—will brief healthcare investors on how their companies fared in 2023, and provide insights on what to expect in 2024.

And, Anne Wojcicki’s billions have vanished. 23andMe’s valuation has crashed 98% from its peak and NASDAQ has threatened to delist its sub-$1 stock. Wojcicki reduced staff by a quarter last year through three rounds of layoffs and a subsidiary sale. The company has never made a profit and is burning cash so quickly it could run out by 2025.

CITE: https://www.r2library.com/Resource

COMMENTS APPRECIATED

Thank You

***

***

“23andMe” Hacked & “Neuralink” Device Defective?

By Staff Reporters

***

***

In a significant breach of privacy, hackers gained access to the DNA relatives data of 6.9 million users on 23andMe, posing serious questions about the security measures in place for our most personal data.

Meanwhile, Neuralink, the brain-computer interface company, faced disturbing reports about its clinical trials. Allegedly, up to a dozen monkeys suffered severe adverse effects, including brain swelling and partial paralysis, after being implanted with the Neuralink device.

Neuralink Corp. is an American company that is developing brain computer interfaces (BCIs) as of 2022. Founded by Elon Musk and a team of seven scientists and engineers, Neuralink was launched in 2016 and was first publicly reported in March 2017.

COMMENTS APPRECIATED

Thank You

***

***

On CRISPR Gene Editing

DEFINITION: CRISPR is a family of DNA sequences found in the genomes of prokaryotic organisms such as bacteria and archaea. These sequences are derived from DNA fragments of bacteriophages that had previously infected the prokaryote. They are used to detect and destroy DNA from similar bacteriophages during subsequent infections

CITE: https://www.amazon.com/Dictionary-Health-Information-Technology-Security/dp/0826149952/ref=sr_1_5?ie=UTF8&s=books&qid=1254413315&sr=1-5

***

A Gene Editing Breakthrough
For the first time, CRISPR technology has been used to successfully treat disease in vivo, or inside the human body.

That big medical news was announced Saturday by the biotech startup Intellia Therapeutics and its partner Regeneron, which said their gene-editing techniques reduced the amount of harmful liver protein associated with a genetic nerve disorder. 

What is CRISPR? It stands for “clustered regularly interspaced short palindromic repeats,” and it’s one of those things humans found in nature and then copied.  Bacteria use CRISPR to repel viruses, but humans have harnessed it to ctrl+c, ctrl+v DNA sequences, potentially leading to a revolution in treating disease.  The two scientists who made that breakthrough in 2012, Jennifer Doudna and Emmanuelle Charpentier, won the Nobel Prize in Chemistry last year (Doudna is also a cofounder of Intellia).

Quote du jour: “There’s a feeling like we’re walking through a door here into all kinds of new possibilities. And there’s not many moments in medicine where you get to experience that,” Intellia CEO John Leonard said.  Looking ahead…expect Intellia shares, which have gained 233% since its 2016 IPO, to pop.

CRISPR/Cas9 Genome Editing Technique - Musicians4Freedom

****

ASSESSMENT: Your thoughts are appreciated.

INVITE DR. MARCINKO: https://medicalexecutivepost.com/dr-david-marcinkos-

CONTACT: Ann Miller RN MH

[Executive Director]

THANK YOU

***

On Consumer DNA Testing

Two states still resist consumer DNA testing

[By MIT Technology Review]

Earlier this month, 55,000 football fans were to receive a giveaway at a Baltimore Ravens game: not a T-shirt or a beer koozie, but a free DNA test. Ultimately, though, Maryland laws nixed the stunt.

Ronni Sandroff explains why.

***

https://www.consumerreports.org/cro/news/2010/09/who-owns-your-dna/index.htm

***

Conclusion

Your thoughts and comments on this ME-P are appreciated. Feel free to review our top-left column, and top-right sidebar materials, links, urls and related websites, too. Then, subscribe to the ME-P. It is fast, free and secure.

Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Medical Executive-Post – is available for seminar or speaking engagements.

Contact: MarcinkoAdvisors@msn.com

Subscribe: MEDICAL EXECUTIVE POST for curated news, essays, opinions and analysis from the public health, economics, finance, marketing, I.T, business and policy management ecosystem.

***

Does the U.S. Supreme Court decision resolve the gene-patenting issue?

Join Our Mailing List

Human Genes are NOT Patentable

By Karen Matthias RN MBA

[Vice-President of Marketing]

Hayes, Inc kmatthias@hayesinc.com

Yesterday, the U.S. Supreme Court unanimously agreed that human genes are not patentable, making a distinction between “natural” DNA found in the human body and the laboratory-created “synthetic” DNA. This opinion reinforces those of many in the genetics community who have argued for years that genes are products of nature rather than inventions.

A Resolution?

But, does the Supreme Court decision completely resolve the gene-patenting issue?

Dr. Diane Allingham-Hawkins, Senior Director, Genetic Test Evaluation Program and Technical Editing at Hayes, Inc., doesn’t think so.

“The Justices compromised somewhat in their decision that while human genes as they exist in nature were ruled not patentable, the opinion allowed that synthetic copies – so-called complementary DNA or cDNA – may be”.

The Court did not rule, however, that cDNA meets all requirements of patent eligibility, just that cDNA would not be considered a ’product of nature’.

Issues Not Addressed

In addition, Dr. Allingham-Hawkins points out what the decision does not address.

“Notably, the opinion clearly stated that it was not ruling on any methods patents related to the two genes or on any applications regarding what Myriad had learned about the genes, leaving the door open for narrower genetic testing patents.

Nevertheless, this is a major victory for the plaintiffs in the case and for patients, who will now have choices related to who performs their genetic testing and options to seek second opinions from independent laboratories.”

###

US supreme court building

More 

Our new white paper on the history of gene patenting in the United States can be an excellent resource as you search for background information on this topic.

Download a complimentary copy here:  http://www.hayesinc.com/hayes/resource-center/white-papers/gene-patenting-in-the-united-states/.

Assessment  

Thanks for considering.

Conclusion

Your thoughts and comments on this ME-P are appreciated. Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, subscribe to the ME-P. It is fast, free and secure.

Link: http://feeds.feedburner.com/HealthcareFinancialsthePostForcxos

Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Medical Executive-Post – is available for seminar or speaking engagements. Contact: MarcinkoAdvisors@msn.com

OUR OTHER PRINT BOOKS AND RELATED INFORMATION SOURCES:

Health Dictionary Series: http://www.springerpub.com/Search/marcinko

Practice Management: http://www.springerpub.com/product/9780826105752

Physician Financial Planning: http://www.jbpub.com/catalog/0763745790

Medical Risk Management: http://www.jbpub.com/catalog/9780763733421

Hospitals: http://www.crcpress.com/product/isbn/9781439879900

Physician Advisors: www.CertifiedMedicalPlanner.org

Product DetailsProduct Details

Should Drugs be Discontinued If DNA Predicts Risks?

On Pharmacogenetic Testing and Genomics – An Invitation

[By Karen D. Matthias RN MBA]

Dr. Marcinko and ME-P Readers

Wouldn’t it be wonderful to test someone’s DNA and know the right drug to prescribe at the right dose the first time without the worry of adverse side effects?  Pharmacogenetics—the manner in which a person’s genes affect their response to drugs, has the potential to do just that.  Genetic and genomic tests hold enormous promise for revolutionizing our medical understanding of a disease.

However, it is irresponsible to suggest that a simple genetic test, at this point in time, can appropriately dictate prescribing practices for certain drugs.

Pharmacogenetic Testing

The use of pharmacogenetic testing in the diagnosis and treatment of cancer has recently created a lot of questions for patients.  A high profile example is whether or not genetic tests can predict the risk of recurrence of breast cancer in women taking tamoxifen.

Our knowledge of how genetics and environment interact to dictate an individual’s response to a given drug is in its infancy. Therefore it is critically important that there is sufficient evidence to support the use of a given test before it is introduced into mainstream medical practice. In most cases, there is not a simple single genetic test that will give us the necessary information.

For example, Hayes has reviewed the evidence behind the pharmacogenetics of response to tamoxifen, and the reality is that there is currently insufficient evidence to conclude that performing a genetic test prior to prescribing this drug has any impact at all on patient outcomes.

Link: http://www.hayesinc.com/hayes/?s=Tamoxifen+

Assessment 

Furthermore, well-designed studies are needed to both confirm the relationship between genetic variants and response to tamoxifen. The critical component is to show that positive changes in patient care can be made in response to the results of genetic testing and to establish what the potential negative repercussions of NOT prescribing these drugs to patients may be.  It is possible that the benefits outweigh the risks, even for patients shown by genetic testing to be less likely to respond to treatment.

Join Our Mailing List 

ME-P Invitation from Hayes, Inc 

Dr. Diane J. Allingham-Hawkins would be available to give you, and your ME-P readers, a perspective on this ongoing genetics testing dialogue. Dr. Allingham-Hawkins is Director of the Genetics Test Evaluation Program at Hayes, Inc., an unbiased, healthcare research and consulting firm that is helping hospitals and insurers cope with the cost and ethical issues related to genetic testing.  She is an outspoken interviewee with deep knowledge of the subject matter and very pointed opinions regarding genetic testing.  A great interview for your consideration.

Contact Info:

Karen D. Matthias – Vice President

Hayes, Inc – 157 S. Broad Street

Lansdale, PA 19446

P: 215-855-0615 x7918

E-mail: kmatthias@hayesinc.com

Channel Surfing the ME-P

Have you visited our other topic channels? Established to facilitate idea exchange and link our community together, the value of these topics is dependent upon your input. Please take a minute to visit. And, to prevent that annoying spam, we ask that you register. It is fast, free and secure.

Conclusion

Your thoughts and comments on this ME-P are appreciated. Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, subscribe to the ME-P. It is fast, free and secure.

Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Medical Executive-Post – is available for seminar or speaking engagements. Contact: MarcinkoAdvisors@msn.com

OUR OTHER PRINT BOOKS AND RELATED INFORMATION SOURCES:

Product DetailsProduct Details

 

Off-Road Touring with Dr. Marcinko [Part IV]

About Atlas Sports Genetics

By Dr. David Edward Marcinko; MBA, CMP™

[Publisher-in-Chief]

Dateline: July 6, 2009people_top

Did you know that for about $150 bucks, Atlas Sports Genetics [ASG], a company in Boulder CO, offers a DNA test kit to evaluate actinin; a protein found in fast-twitch muscle fibers? Yep; it’s true!

About ASG

ATLAS™ stands for Athletic Talent Laboratory Analysis System and is a leading edge athletic talent identification test that uses enhanced DNA analysis to identify those athletes that are genetically predisposed to either speed/power or endurance characteristics. Through the analysis of a specific DNA gene called ACTN3, the SportGene® Test developed by Genetic Technologies in Australia, is now available in the United States through Atlas Sports Genetics.

The Kit

Using a cheek swab sent to the lab, a report on the gene ACTN3 is received by mail several weeks later. The test is touted to be helpful in determining the best sport, or prefect athletic career, for participants. And, it is highly sought after by helicopter parents wishing to pursue a college scholarship or sports contract for junior [i.e., marathoner versus sprinter, etc].

Just take a look here: http://www.atlasgene.com

AssessmentESPN

How did I learn about all this? Why, from an USOEC parent of course, during my travels to Upper Michigan. And me? I’ve been a middle distance runner for 35 years; even with a dislocated finger! LSD anyone; long-slow-distance.

 

About Off Road with Dr. Marcinko

These sporadic off-road segments will continue through-out my 2009 summer promotional tour. On the one hand, formal attendance at several engagements was a bit sparse because of the death of several recent celebrities and entertainer types. On the other hand, local book stores and sponsors noted a spike in our CD and book sales, as well as interest in our online www.CertifiedMedicalPlanner.com program and premier quarterly guide: Healthcare Organizations [Journal of Financial Management Strategies] www.HealthcareFinancials.com

Part I: https://healthcarefinancials.wordpress.com/2009/07/20/off-road-touring-with-dr-marcinko-part-i/

Part II: https://healthcarefinancials.wordpress.com/2009/07/22/off-road-touring-with-dr-marcinko-part-ii/

Part III: https://healthcarefinancials.wordpress.com/2009/07/24/off-road-touring-with-dr-marcinko-part-iii/

Conclusion

And so, your thoughts and comments on this Medical Executive-Post are appreciated. Tell us what you think about the performance predictive power of ACTN3? Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, be sure to subscribe to the ME-P. It is fast, free and secure.

Link: http://feeds.feedburner.com/HealthcareFinancialsthePostForcxos

Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Executive-Post – is available for seminar or speaking engagements. Contact: MarcinkoAdvisors@msn.com 

Get our Widget: Get this widget!

Our Other Print Books and Related Information Sources:

Practice Management: http://www.springerpub.com/prod.aspx?prod_id=23759

Physician Financial Planning: http://www.jbpub.com/catalog/0763745790

Medical Risk Management: http://www.jbpub.com/catalog/9780763733421

Healthcare Organizations: www.HealthcareFinancials.com

Health Administration Terms: www.HealthDictionarySeries.com

Physician Advisors: www.CertifiedMedicalPlanner.com

Subscribe Now: Did you like this Medical Executive-Post, or find it helpful, interesting and informative? Want to get the latest ME-Ps delivered to your email box each morning? Just subscribe using the link below. You can unsubscribe at any time. Security is assured.

Link: http://feeds.feedburner.com/HealthcareFinancialsthePostForcxos

Sponsors Welcomed

And, credible sponsors and like-minded advertisers are always welcomed.

Link: https://healthcarefinancials.wordpress.com/2007/11/11/advertise

23 and Me

Join Our Mailing List

Personal DNA Analysis and Reporting 

[By Staff Reporters]

Ever wondered why you were left-handed and your sibling or parent wasn’t?

A not-so-new new company, 23andMe, provides an analysis of DNA, where you can learn more about yourself, your immediate family and even your ancestry.

Target Markets

Those who would be especially interested in this personal genome service include:

Methodology

Customers [sic patients] submit a small saliva sample that is processed using a proprietary custom DNA chip. The resulting data is then presented on a secure website using interactive tools that offer information about ancestry, inherited traits and disease risk.

Board of Directors

This is no lightweight company. It technology founders include:

  • Linda Avey
  • Anne Wojcicki
  • Esther Dyson

While its’ medical advisors are:

  • Uta Francke; MD [Professor of Genetics and Pediatrics, Stanford University].
  • Itsik Pe’er; PhD [Assistant Professor of Computer Science, Columbia University].
  • Peter A. Underhill; PhD [Senior Research Scientist, Stanford University].

Assessment

You can also better understand your genetic tendencies for things like obesity or health issues.

There is even an interactive blog: http://spittoon.23andme.com

Users can find other members with similar genetic makeup and start discussions. And, it is $999 to order a kit for the DNA test. 

Conclusion

Your thoughts and comments on this ME-P are appreciated. Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, subscribe to the ME-P. It is fast, free and secure.

Link: http://feeds.feedburner.com/HealthcareFinancialsthePostForcxos

Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Medical Executive-Post – is available for seminar or speaking engagements. Contact: MarcinkoAdvisors@msn.com

OUR OTHER PRINT BOOKS AND RELATED INFORMATION SOURCES:

DICTIONARIES: http://www.springerpub.com/Search/marcinko
PHYSICIANS: www.MedicalBusinessAdvisors.com
PRACTICES: www.BusinessofMedicalPractice.com
HOSPITALS: http://www.crcpress.com/product/isbn/9781466558731
CLINICS: http://www.crcpress.com/product/isbn/9781439879900
ADVISORS: www.CertifiedMedicalPlanner.org
PODIATRISTS: www.PodiatryPrep.com
BLOG: www.MedicalExecutivePost.com
FINANCE: Financial Planning for Physicians and Advisors
INSURANCE: Risk Management and Insurance Strategies for Physicians and Advisors

Product DetailsProduct DetailsProduct Details